New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Site Search
Showing 1 - 4 of 4 results
Press Release
|
April 19, 2022
|
3 min read
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
News
|
March 7, 2024
|
2 min read
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
News
|
March 18, 2024
|
2 min read
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Press Release
|
April 3, 2024
|
3 min read